| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ZANAMIVIR | IMPURITIES/Organic Impurities/Chromatographic system | USP37–NF32 | 5197 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Column: Change 5-μm packing L##1 to: 5-μm packing L82 |
| SAW PALMETTO EXTRACT | COMPOSITION/Content of Long-Chain Alcohols and Sterols | USP37–NF32 | 5545 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 3 of Acceptance criteria:Add The lipophilic Extract contains 0.15%–0.35% of long-chain alcohols, and the hydroalcoholic Extract contains 0.01%–0.15% of long-chain alcohols on the anhydrous basis. |
| TRIBASIC CALCIUM PHOSPHATE | ASSAY/Procedure | USP37–NF32 | 5883 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Delete the subsection Blank: Proceed as directed in the Analysis, omitting the test specimen. AND Equation in Analysis: Change Result = {[VS − VB) × M × F]/W} × 100 to: Result = [(V… Read More |
| TRIBASIC CALCIUM PHOSPHATE | IMPURITIES/Dibasic Salt and Calcium Oxide | USP37–NF32 | 5883 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Delete the subsection Blank: 25.0 mL of Titrant |
| COPOVIDONE | IMPURITIES/Limit of Monomers (1-Vinyl-2-Pyrrolidone, Vinyl Acetate, and 2-Pyrrolidone) | USP37–NF32 | 5938 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 29 of Analysis: Change Calculate the content of 2-pyrrolidinone to: Calculate the content of 2-pyrrolidone |
| CHLORPHENIRAMINE MALEATE | SPECIFIC TESTS/Optical Rotation, Specific Rotation <781> | First Supplement to USP37–NF32 | 6617 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Sample: Change 100 mg/mL in water to: 100 mg/mL in water at 20° |
| ERYTHROMYCIN DELAYED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 1/Buffer stage | First Supplement to USP37–NF32 | 6633 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution: Change 0.28 mg/mL of USP Erythromycin RS in Medium to: Dissolve USP Erythromycin RS in Medium to obtain a concentration similar to that of the Sample solution. AND Line 1 of Sample solution: Change Pass portions of… Read More |
| TRAZODONE HYDROCHLORIDE | IMPURITIES/Limit of Trazodone Related Compound F and Cyclophosphamide Related Compound A/Chromatographic system/MS conditions | First Supplement to USP37–NF32 | 6708 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 4 of Acquisition mode:Change 272 to: 273 |
| TRAZODONE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | First Supplement to USP37–NF32 | 6708 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 2 of USP Trazodone Related Compound D RS: Change (2-{3-[4-(4-Bromophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-α]pyridin-3(2H)-one hydrochloride. to: 2-{3-[4-(3-Bromophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-α]pyridin-3(2H)-one hydrochloride. |
| GLYCERYL BEHENATE | DEFINITION | Second Supplement to USP37–NF32 | 7077 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 7: Change behenic (docosanic) acid to: behenic (docosanoic) acid |
| HYDROXYPROPYL CELLULOSE | ASSAY | Second Supplement to USP37–NF32 | 7080 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Internal standard solution: Change Methycyclohexane to: Methylcyclohexane |
| POLYSORBATE 80 | SPECIFIC TESTS/Fats and Fixed Oils, Acid Value <401> | Second Supplement to USP37–NF32 | 7089 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Analysis: Change with 0.1 N potassium hydroxide or 0.1 N sodium hydroxide to: with 0.1 N potassium hydroxide VS or 0.1 N sodium hydroxide VS |
| MEBENDAZOLE | ASSAY/Procedure | Second Supplement to USP37–NF32 | 7199 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 3 of Analysis: Change Calculate the percentage of each impurity in the portion of Oral Suspension taken: to: Calculate the percentage of mebendazole (C16H13N3O3) in the portion of Mebendazole taken: |
| SODIUM PICOSULFATE | CHEMICAL INFORMATION | Second Supplement to USP37–NF32 | 7253 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 5: Change Disodium 4,4′-(pyridin-2-ylmethanediyl)dibenzenesulfonate to: Disodium 4,4′-(pyridin-2-ylmethanediyl)dibenzenesulfate |
| GANODERMA LUCIDUM FRUITING BODY | COMPOSITION/Content of Triterpenoic Acids | Revision Bulletin (Official August 01, 2014) | Online | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution A: Change USP Ganoderic Acid RS to: USP Ganoderic Acid A RS AND Line 3 of variable definition list in Analysis: Change rS = peak area of ganoderic acid in Standard solution A to: rS… Read More |
| GANODERMA LUCIDUM FRUITING BODY | SPECIFIC TESTS/Botanical Characteristics | Revision Bulletin (Official August 01, 2014) | Online | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 6 of Macroscopic: Change concentrically culcate to: concentrically sulcate |
| GANODERMA LUCIDUM FRUITING BODY POWDER | COMPOSITION/Content of Triterpenoic Acids | Revision Bulletin (Official August 01, 2014) | Online | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution A: Change USP Ganoderic Acid RS to: USP Ganoderic Acid A RS AND Line 3 of variable definition list in Analysis: Change rS = peak area of ganoderic acid in Standard solution A to: rS… Read More |
| FENTANYL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP37–NF32 | Online | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Delete USP Fentanyl Related Compound C RS AND Delete USP Fentanyl Related Compound F RS |
| NIFEDIPINE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | Second Supplement to USP37–NF32 | Online | 21-Nov-2014 | 1-Dec-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Solution A: Change sodium phosphate to: dibasic sodium phosphate |
| BETAMETHASONE SODIUM PHOSPHATE | IMPURITIES/Limit of Free Betamethasone | USP37–NF32 | 1965 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Sample stock solution: Change 1.0 mg/mL of Betamethasone Sodium Phosphate in water to: 1.0 mg/mL of Betamethasone Sodium Phosphate in water, prepared as follows. Dissolve 25.0 mg of Betamethasone Sodium Phosphate in water to make 25.0 mL. |
| CALCIUM GLUCONATE INJECTION | Identification | USP37–NF32 | 2089 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Identification test A: Change A volume of Injection diluted, if necessary, with water to obtain a test solution of calcium gluconate (1 in 100) responds to Identification test B under Calcium Gluconate. to: Dissolve a quantity of it in water to… Read More |
| DACARBAZINE | USP Reference standards <11> | USP37–NF32 | 2504 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 3 of USP Dacarbazine Related Compound B RS: Change C4H3N5O 137.10 to: C4H3N5O · H2O 155.12 |
| ESCITALOPRAM ORAL SOLUTION | IMPURITIES/Organic Impurities | USP37–NF32 | 2580 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Row 6 of Column 1 of Table 3: Change Desfluorocitalopramf to: Desfluorocitalopramf,c |
| DIDANOSINE DELAYED-RELEASE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Analysis | USP37–NF32 | 2603 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 11 of the variable definition list: Change CS = concentration of didanosine in the Standard solution (mg/mL) to: CS = concentration of USP Didanosine Related Compound A RS in the Standard solution for the Acid stage or… Read More |
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS | IMPURITIES/Organic Impurities/Chromatographic system | USP37–NF32 | 2739 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 2 of Detector 2: Change Monitor the signal at 344 nm between 37 and 42 min. to: Monitor the signal at 344 nm for ethinyl estradiol related compound B (typically between 37 and 42 min). |
| IRINOTECAN HYDROCHLORIDE INJECTION | IMPURITIES/Organic Impurities | USP37–NF32 | 3403 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Row 3 of Column 1 of Table 2: Change Camptothecinb to: Camptothecinb,d AND Row 5 of Column 1: Change 7-Ethylcamptothecinc to: 7-Ethylcamptothecinc,d AND Add a footnote: dThese process impuritiesare… Read More |
| KETOPROFEN EXTENDED-RELEASE CAPSULES | ASSAY/Procedure/System suitability/Suitability requirements | USP37–NF32 | 3469 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Tailing factor: Change NLT 1.5 to: NMT 1.5 |
| KETOPROFEN EXTENDED-RELEASE CAPSULES | PERFORMANCE TESTS/Uniformity of Dosage Units <905>/System suitability/Suitability requirements | USP37–NF32 | 3469 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Tailing factor: Change NLT 1.5 to: NMT 1.5 |
| OXYBUTYNIN CHLORIDE | SPECIFIC TESTS/Loss on Drying <731> | USP37–NF32 | 4129 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Acceptance criteria: Change NMT 3.0% to: NMT 3% |
| PSEUDOEPHEDRINE HYDROCHLORIDE | ASSAY/Procedure | USP37–NF32 | 4481 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 2 of System suitability solution: Change 0.02 mg/mL of USP Ephedrine Sulfate RS to: 0.002 mg/mL of USP Ephedrine Sulfate RS |
| WATER FOR HEMODIALYSIS | CHEMICAL INFORMATION | USP37–NF32 | 5173 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
| WATER FOR INJECTION | CHEMICAL INFORMATION | USP37–NF32 | 5173 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
| STERILE WATER FOR INHALATION | CHEMICAL INFORMATION | USP37–NF32 | 5174 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
| STERILE WATER FOR INHALATION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5174 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS |
| STERILE WATER FOR INJECTION | CHEMICAL INFORMATION | USP37–NF32 | 5175 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
| STERILE WATER FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5175 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS |
| STERILE WATER FOR IRRIGATION | CHEMICAL INFORMATION | USP37–NF32 | 5175 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
| STERILE WATER FOR IRRIGATION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5175 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS |
| PURE STEAM | CHEMICAL INFORMATION | USP37–NF32 | 5176 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
| STERILE PURIFIED WATER | ADDITIONAL REQUIREMENTS | USP37–NF32 | 5176 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add a section: USP Reference Standards <11> USP 1,4-Benzoquinone RS USP Sucrose RS |
| CELLACEFATE | ASSAY/Content of Acetyl | USP37–NF32 | 5919 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 12 of Analysis: Result = {[(P − 0.5182 × B)/(100 − B)] − (0.5772 × C)} × 100 to: Result = 100 × [P − (0.5182 × B)]/(100 − B) − (0.5772 × C) |
| POWDERED CELLULOSE | IDENTIFICATION/B. Procedure | USP37–NF32 | 5923 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Fourth equation in Analysis: Change Result = 95 × [η]c/WS × [(100 − %LOD)/100] to: Result = [95 × [η]c]/{WS × [(100 − %LOD)/100]} |
| ETHYLCELLULOSE DISPERSION TYPE B | ASSAY/Procedure | USP37–NF32 | 5981 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 3 of Analysis: Change Calculate the percentage of ethylcellulose in the portion of Ethylcellulose Dispersion Type B taken: to: Calculate the percentage of the labeled amount of ethylcellulose in the portion of Ethylcellulose Dispersion Type B taken: |
| CHLORPHENIRAMINE MALEATE | IMPURITIES/Organic Impurities | First Supplement to USP37–NF32 | 6617 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Standard solution: Change 1.1 μg/mL of USP Chlorpheniramine Maleate RS in Diluent, to: 1.4 μg/mL of USP Chlorpheniramine Maleate RS in Diluent, |
| DEXCHLORPHENIRAMINE MALEATE | IMPURITIES/Organic Impurities | First Supplement to USP37–NF32 | 6626 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Standard solution: 2.2 μg/mL of USP Dexchlorpheniramine Maleate RS in Diluent, to: 2.8 μg/mL of USP Dexchlorpheniramine Maleate RS in Diluent, |
| DACARBAZINE FOR INJECTION | IMPURITIES/Limit of 2-Azahypoxanthine | Second Supplement to USP37–NF32 | Online | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 2 of Analysis: Change 2-azahypoxanthine monohydrate to: 2-azahypoxanthine |
| GENERAL NOTICES TO USP-NF | 6. TESTING PRACTICES AND PROCEDURES/6.50. Preparation of Solutions | First Supplement to USP37–NF32 | 6291 | 25-Jul-2014 | 1-Aug-2014 | USP38–NF33 | USP38–NF33 | Line 6 of 6.50.20. Solutions: Change An expression such as “(1 in 10)” means that 1 part by volume of a liquid shall be diluted with a sufficient quantity of the diluent or solvent to make the volume of the finished solution 10 parts by volume. An expression such as “(20:5:2… Read More |
| <795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS | DEFINITIONS | USP37–NF32 | 403 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Beyond-Use Date (BUD): Change The date after which a compounded preparation should not to be used; to: The date after which a compounded preparation shall not be used; |
| <1788> METHODS FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS | LIGHT OBSCURATION PARTICLE COUNT TEST/Instrument Standardization Tests/Particle Counting Accuracy—System Suitability | USP37–NF32 | 1301 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 26 of Method 1—MWHC Instruments: Change PB is the average particle count obtained from the suspension; to: PS is the average particle count obtained from the suspension; |
| ALLOPURINOL | USP Reference standards <11> | USP37–NF32 | 1649 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 2 of USP Allopurinol Related Compound C RS: Change N-(4H-1,2,4-Triazol-4-yl)-1H-pyrazole-4-carboxamide. to: 5-(4H-1,2,4-Triazol-4-yl)-1H-pyrazole-4-carboxamide. |